| |
Read More About Dr Goffe
Education and Training
- 1959 Bachelor Science, University of Washington, Seattle, WA
- 1962 Medical Doctorate, University of Washington, Seattle, WA
- 1962-1963 Internship, Internal Medicine, Harborview Medical Center, Seattle, WA
- 1963-1964 Residency, Internal Medicine, University of Washington Affiliated Hospitals, Seattle, WA
- 1966-1968 Fellowship in Dermatology, University of Washington, Seattle, WA
Professional Experience
- 1964-1966 Epidemic Intelligence Service Officer, Communicable Disease Center, Hospital Infections Unit, Atlanta, GA
- 1965 Peace Corps - Turkey
- 1966 Smallpox vaccination (WHO) West Africa
- 1968-1970 Dermatology, Polyclinic, Seattle, WA
- 1970-2004 Dermatology, Minor & James
Medical, 515 Minor Avenue, Suite 200,
Seattle, WA (206) 386-9500
Board Certification
- 1969 American Board of Dermatology
- 1979 American Board of Dermatopathology
Licensure to Practice
- 1963-Present Washington State #MD00008765
^ Top
Professional Organizations
- 1968-present American Medical Association
- 1968-present King County Medical Society
- 1968-present American Academy of Dermatology
- 1968-present Seattle Dermatology Society
- 1968-present Seattle Dermatopathology Society
- 1980s National Psoriasis Foundation-Medical Advisory Board
- 2002 Psoriasis Therapies Educational Summit/AAD
Clinical Appointments
- 1978-1999 Medical Director, Psoriasis Treatment Center, Seattle, WA
- 1982-1999 Medical Director, Laser Clinic, Seattle, WA
Hospital Appointments
- 1969-present Providence Medical Center, Seattle, WA
- 1968-present Swedish Medical Center, Seattle, WA
- 1968-present University of Washington Hospital/Medical Center, Seattle, WA
Teaching Appointments
- 1992-present Clinical Professor, Department of Medicine, Division of Dermatology, University of Washington School of Medicine, Seattle, WA
- Dermatology Training, Community Family Practice Clinic, Swedish Medical Center, Seattle, WA
- 1968-1992 Clinical Associate Professor, Department of Medicine, Division of Dermatology, University of Washington School of Medicine, Seattle, WA
^ Top
Publications
- Advance in Therapy, Response of Tinea Corporis/Cruris & Tinea (Pityriasis)
Versicolor to Once Daily Topical Treatment with
Bifonazole Cream -- A Safety & Efficacy Study,
p. 289.
- International Telesymposium on Recent Trends
in the Discovery, Development & Evaluation of
Anifungal Agents, May 1987, Recent Trends in
the Discovery, Development & Evaluation of
Antifungal Agents, p. 423.
- Journal of Geriatric Dermatology, Seattle
Psoriasis Treatment Center Experience. March
1995.
- Highton A., Quell J., Goffe B.,
Calcipotriene ointment 0.005% for psoriasis: a
safety and efficacy study. Journal of the Americal Academy of Dermatology. January 1995,
p. 67-72
- Guzzo C., Lazarus G., Goffe B., Katz I., Lowe
N., and Pincus S.: Topical Calcipotriene Has No
Effect on Calcium and Bone Metabolism of
Psoriasis Patients., Journal of the American
Academy of Dermatology. March 1996, p. 429-33.
- Tack, K., Wilks, N., Semerdjian, G., Frazier
C., Shirin K., Puopolo A., Crossland S., Goffe
B., Millikan L., Cefpodoxime Proxetil in the
Treatment of Skin and Soft Tissue Infections,
Journal of the American Academy of Dermatology.
1992.
- M. Lebwohl, D. Breneman, B. Goffe, J.
Crossman, M. Ling, J. Milbauer, S. Pincus, et
al. Tazarotene 0.1% gel plus corticosteroid
cream in the treatment of plaque psoriasis,
Journal of the American Academy of Dermatology,
1996.
- Ling, M., Swinyer L., Goffe B., et al. A
placebo-controlled, randomized, double-blind
trial of once weekly fluconazole for 4, 6 or 9
months of treatment for distalsubungal
onychomycosis of the toenail, Journal of the
American Academy of Dermatology, 1997.
- Abrams, J., Lebwohl, M., Jegasothy, B.,
Goldfarb, M., Goffe, B., et al.
CTLA4Ig-mediated Blockade of T Cell
Costimulation in Patients with Psoriasis
Vulgaris, The Journal of Clinical
Investigation, May 1999.
- Mease, P., Goffe, B., et al. Etanercept in
the Treatment of Psoriatic Arthritis and
Psoriasis: A Randomised Trial. The Lancet, July
2000
- Goffe, B., Practical Applications of Anti-TNF
Therapy in Dermatology Practice, Skin & Allergy
News, April 2003
- Goffe, B., Cather, J., Etanercept: An
Overview, J Am Acad Dermaltol, 2003;49:S105-11
- Gottlieb, A., Goffe, B. et al. Etanercept in
the Treatment of Psoriasis, awaiting
publication
- Goffe, B., Mease, P. Does your
psoriasis patient have psoriatic Arthritis
Part 1: Diagnosis and Part 2: Impact on
Treatment Choices. Journal of the American Academy of
Dermatology, awaiting publication
- Leonardi, C., Powers, J., Matheson, R., Goffe,
B. et al. Etanercept as Monotherapy in Patients
with Psoriasis: A Multicenter Randomized Study.
New England Journal of Medicine, awaiting
publication
^ Top
Clinical Research Activities
- 1991 Cefopodoxime proxetil in the treatment of skin and soft tissue infections, Parke Davis
- 1994 Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study, Bristol Myers Squibb
- 1996 Tacrolimus in Adult Patients with Atopic Dermatitis, Fujisawa
- 1996 Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis, Allergan
- 1996 Fluconazole in the treatment of Onychomycosis, Pfizer
- 1997 Gatifloxicin versus Levofloxacin in the treatment of uncomplicated skin infection
- 1997 Zemaphyte Eczema Granules in the treatment of severe, dry, atopic dermatitis
- 1997 CTLA4Ig in patients with Psoriasis vulgaris, Bristol-Myers Squibb
- 1998 Tazarotene gel in the treatment of plaque psoriasis, Allergan
- 1998 Cefditoren pivoxil and Cefuroxime Axetil in the treatment of patients with skin or skin structure infection, TAP
- 1999 Tacrolimus in Patients with Atopic Dermatitis, Fujisawa
- 1999 Maxacalcitol Topical Vitamin D analog for the treatment of psoriasis, Schering Plough
- 1999 Enbrel® in the treatment of Psoriatic Arthritis and Psoriasis, Investigator IND support: Immunex
- 2000 LFA3TIP for the treatment of Psoriasis, Biogen
- 2000 LFA3TIP Immune Response Study in Patients with Psoriasis, Biogen
- 2000 ACD2059g for the treatment of Psoriasis, Genentech
- 2000 Enbrel® for the treatment of Psoriasis, Immunex
- 2001 BIRB 796 PO BID in Patients with Plaque-type Psoriasis, Boehringer Ingelheim
- 2001 Topical TNF receptor inhibitor in Patients with Psoriasis, ISIS Pharmaceuticals
- 2001 Avandia® in Patients with Plaque Type Psoriasis, GlaxoSmithKline
- 2001 Tazorac Gel in Pregnant Female Subjects with Psoriasis, Allergan
- 2001 Phase III Trial of Enbrel® in Patients with Psoriasis, Immunex
- 2002 Protopic in Patients with Psoriasis, Fujisawa
- 2002 PVAC in Patients with Plaque Type Psoriasis, Corixa
- 2002 Raptiva® in Moderate to Severe Psoriasis, Genentech
- 2002 Alefacept in Psoriasis, Biogen
- 2003 Allegra® in Chronic Idiopathic Urticaria, Aventis
- 2003 Phase III double-dose Trial of Enbrel® in Patients with Psoriasis, Amgen
- 2003 Remicade® in Psoriasis, Centocor
- 2003 Protopic Gel in Psoriasis, Fujisawa
- 2003 Tazorac® for Psoriasis in Pregnant Female Population, Allergan
- 2003 Phase IV Observational Study of Enbrel® in Psoriatic Arthritis (Derm-population), Amgen
^ Top
|
|
